Cannabis Edibles for Appetite Loss in Older Adults: The Munchies Meet the Evidence

The munchies are real, and they are the worst possible starting point for an 85-year-old who has stopped finishing meals. In 2025 a Copenhagen team ran the trial this whole idea needed. Seventeen hospital patients aged 65 and over, all with poor appetite, got a mouth spray carrying 8.1 mg of THC and 7.5 mg of CBD twice in one day, then placebo on a separate day, and were fed identical test meals so every bite could be counted. Cannabis added 10 calories (the confidence interval ran from 55 fewer to 75 more), a result the authors read as no improvement. That is about one cracker.

So here is the position this page takes. In an older adult with poor appetite or unplanned weight loss, an edible is at most a narrow, low-dose, supervised option, and it comes after someone has asked why the appetite went in the first place. The geriatric literature lists plenty of reasons, and most of them have fixes that have nothing to do with a dispensary. The cancer version of this question, where wasting is driven by metabolism more than by hunger, has its own page: our cancer cachexia page covers why the appetite trials there came up short, and none of that is repeated here.

Does cannabis stimulate appetite in older adults?

Weakly and inconsistently. The one blinded trial built around older adults with poor appetite found no meaningful change in calories eaten. Two older dronabinol studies in Alzheimer's patients and nursing home residents reported weight trends, but they enrolled 28 people or fewer, and the nursing home study had no placebo group at all.

Wilson's residents started at a mean of 105.7 lb. Seven of the 11 who kept losing weight on dronabinol died, against 4 of the 15 who gained, and the St. Louis authors read a failure to respond as a sign of higher death risk. A look back at charts from five facilities cannot say the drug changed anyone's outcome.

The dementia evidence as a whole is thin. A 2021 Cochrane review found four trials with 126 participants, all testing THC or its synthetic cousins, and concluded it cannot be certain whether cannabinoids help or harm people with dementia. The largest of those, van den Elsen's 2015 Neurology trial, gave 1.5 mg of THC three times a day for three weeks and found no benefit on behavioral symptoms over placebo. A drug that does nothing measurable at 4.5 mg a day, and nothing measurable for calories at 16.2 mg, is a thin foundation.

What does the dronabinol label say about older patients?

Dronabinol, the prescription THC capsule sold as Marinol, is approved for anorexia with weight loss in AIDS and for chemotherapy nausea, and nothing else. Its label says elderly patients are more sensitive to its mental and blood pressure effects, and that the trials behind it included too few people over 65 to tell whether they respond differently.

The label's adult starting dose for the AIDS indication is 2.5 mg twice daily, one hour before lunch and dinner. For elderly patients it suggests 2.5 mg once daily before dinner or at bedtime, to reduce the risk of central nervous system effects. It says elderly patients with dementia face higher fall risk from the drug's somnolence and dizziness and should be placed on fall precautions before starting. And it notes something an edible buyer never hears: the appetite effect can last 24 hours or longer, well past the 4 to 6 hours of psychoactive effect the same label lists.

The 2023 American Geriatrics Society Beers Criteria, the standard list of drugs to avoid or use carefully after 65, has no entry for dronabinol or cannabis. The appetite drug it does flag is megestrol, marked avoid, with the reason given as minimal effect on weight and a higher risk of blood clots and possibly death. Absence from the list says nobody has studied cannabinoids in older adults well enough to grade them, and a gap in the evidence makes a poor substitute for a clean bill of health.

Why did the appetite drop in the first place?

Usually for a reason a clinician can find. A 2022 task force of the International Conference on Frailty and Sarcopenia Research lists depression, dementia, medications, poor teeth, swallowing problems and other chronic disease, along with loneliness, poverty and food insecurity, as drivers of appetite loss in older people. Each points somewhere other than a gummy.

The same task force made the point that matters most here: giving an appetite-stimulating drug to someone whose appetite loss comes from depression is questionable, because it leaves the cause untouched. The same logic covers a cracked molar, a new pill that makes everything taste of metal, or a spouse who died and took dinner conversation with them. A 2019 systematic review of treatments for the anorexia of aging found 18 studies across nine kinds of intervention, from flavor enhancement to mealtime assistance to oral nutritional supplements, and only two tested a medication.

What are the risks of edibles for older adults?

Dizziness, drowsiness, low blood pressure on standing, confusion and drug interactions, in a group already prone to falls. Emergency visits are rising too. In California, cannabis-related emergency visits among adults 65 and over went from 20.7 to 395.0 per 100,000 visits between 2005 and 2019, and in Ontario the steepest jump followed legal edibles.

The Ontario numbers come from Stall's 2024 research letter in JAMA Internal Medicine. Over eight years there were 2,322 emergency visits for cannabis poisoning in Ontarians 65 and older. The rate went from 5.8 per 100,000 person-years before legalization to 15.4 once dried flower was legal and 21.1 once edibles reached shelves in January 2020, three times the starting rate after adjustment. Alcohol intoxication at the same visit went with a rate more than four times higher. Among the possible explanations the authors list are accidental ingestion and the lack of any dosing instructions written for older adults.

Smaller trials show where the trouble starts. In healthy volunteers with a mean age of 72, single doses of 3, 5 and 6.5 mg of THC were tolerated, drowsiness was the most common complaint at 27%, side effects climbed at 6.5 mg, and blood levels varied widely between people on the same dose. In community-dwelling dementia patients, 1.5 mg twice a day increased sway when they stood with their eyes closed. Nobody fell, though each arm lasted three days. The blood pressure and falls problem gets fuller treatment on our Parkinson's tremor page, where it matters even more.

Interactions are the part a caregiver can act on. The dronabinol label warns of added dizziness, confusion and sedation alongside other sedating drugs, added cardiac effects such as low blood pressure and fainting alongside drugs that act on the heart and circulation, and closer monitoring with warfarin and other narrow-margin drugs. That makes the doctor who manages the person's medications the first call before any cannabis, and the call matters most for anyone on a blood thinner, a sleeping pill or anxiety drug, or a blood pressure tablet.

Who decides when the person cannot?

A clinician and the legal surrogate, through a formal process. AMDA, the society for post-acute and long-term care medicine, cautions against widespread routine use of marijuana in nursing homes, and where it is used, its 2019 statement asks for informed consent from the surrogate, agent or guardian when the resident cannot decide.

The same statement wants a written facility policy, a clinician's recommendation, dispensing by a state-approved caregiver, and monitoring for adverse events. Crumbling a gummy into applesauce for someone who can no longer weigh in skips every one of those steps.

Is CBD good for low appetite?

No trial shows CBD raising appetite, and the prescription CBD label points the other way. In the Epidiolex epilepsy trials, decreased appetite hit 16% of patients at 10 mg per kg a day and 22% at 20 mg per kg, against 5% on placebo, and weight loss showed up at 3 to 5% against 1%.

Those are prescription doses, 700 mg a day and up for a 70 kg adult, far above anything in a gummy tin. Still, a CBD product sold to someone who has stopped eating has no evidence for the job and a drug label listing the opposite effect. The Copenhagen spray carried nearly as much CBD as THC and moved nothing either.

Which low-dose products allow a small first dose?

Pieces dosed at 2.5 mg of THC or less, which our dosing guide puts at the microdose end of its scale (1 to 2.5 mg). They take 30 minutes to 2 hours to start and run 4 to 8 hours, per our guide to how long edibles last, a long night of bathroom trips to watch over.

Four products, specs checked on the brands' own sites and prices pulled from the same delivery menu on October 27, 2026:

The Wyld is the honest critique. Its 2.5 mg dose is a quarter of a 4 g gummy, which means a knife and a cutting board, steady hands and decent eyesight, the three things arthritis, tremor and cataracts take first. Saving 10 cents a dose is not worth handing that job to someone with tremor or cataracts. Wyld also says packaging and dosing vary by state.

The Petra mint is the opposite problem in miniature: at 0.75 g it is small enough to drop and lose on a carpet, which is a less dangerous failure. The Moroccan Mint lists matcha, so the Cinnamon is the evening tin. Cann's 2 mg can is the gentlest dose here, and it is also eight ounces of fluid to get through for someone whose whole problem is not wanting to take anything in. A tin of 40 mints at $23.50 is a lot of supply for an experiment that, per the best trial available, has about a cracker's worth of upside.